Safety and efficacy of two starting doses of vandetanib in advanced medullary thyroid cancer

Author(s):
Hu, M.M.I.; Elisei, R.; Dedecjus, M.; Popovtzer, A.; Druce, M.; Kapiteijn, E.; Pacini, F.; Locati, L.; Krajewska, J.; Weiss, R.; Gagel, R.F.
Published
2019
Publication type
Article / Letter to editor
vandetanibmedullary thyroid cancersafetyefficacy
Date issued
2019-02-28
Language
English
Is part of
Endocrine-Related Cancer (2019), Vol. 26, no. 2, p. 241-250
hdl
1887/119581
doi
10.1530/ERC-18-0258